

# LONG-TERM EFFECTIVENESS OF OMALIZUMAB FOR CHRONIC IDIOPATHIC URTICARIA IN CLINICAL PRACTICE

M.D. GIL-SIERRA<sup>1</sup>, M.D.P. BRICEÑO-CASADO<sup>2</sup>, C. MORENO-RAMOS<sup>3</sup>, E. RIOS-SANCHEZ<sup>3</sup>, J.M. BORRERO-RUBIO<sup>3</sup>

<sup>1</sup>HOSPITAL UNIVERSITARIO PUERTO REAL, PHARMACY, PUERTO REAL, SPAIN

<sup>2</sup>HOSPITAL NUESTRA SEÑORA DEL PRADO, PHARMACY, TALAVERA DE LA REINA, SPAIN

<sup>3</sup>HOSPITAL UNIVERSITARIO DE PUERTO REAL, PHARMACY, PUERTO REAL, SPAIN

4. Historical research

5PSQ-060

## BACKGROUND

**Omalizumab** is a monoclonal antibody used in patients with antihistaminic refractory **chronic idiopathic urticaria** (CIU). Real-life data on the **long-term effectiveness** of omalizumab could provide relevant information for healthcare professionals

## AIM

To evaluate the **long-term effectiveness** of omalizumab in CIU in clinical practice

## MATERIAL AND METHODS

**Descriptive retrospective** study between **October 2020** and **June 2021**

**DATA:** Farmatools® application and digital clinical history

### Definitions for effectiveness

- Gender
- Age
- Previous therapy
- Duration of treatment
- Regimen with omalizumab

- Baseline Urticaria Activity Score during a 7-day period (UAS7).


- No response to therapy (**NR**): UAS7>15.
- Mild disease (**MD**): UAS7=7-15.
- Adequate disease control (**DC**): UAS7≤6.
- Total response (**TR**): UAS7=0.
- Patients with **NR** and **omalizumab therapy suspension** in a certain month were considered as NR in the **following months**

### EFFECTIVENESS



## RESULTS

- **Patients:** 47 patients
- **Gender:** 23.4% were male and 76.6% were female
- **Age:** median of 45 (11-76) years.
- **Previous therapy:** all patients received H1 antihistamines and 72.3% were treated with corticosteroids.
- **Duration of treatment with omalizumab:** median of 18 (11-56) months.
- **Omalizumab regimens:**
  - 19.1% of patients were treated with 150 mg/28 days
  - 78.7% of patients received 300 mg/28 days
  - 2.2% were treated with 450 mg/28 days
- **Baseline UAS7:** All patients presented NR at baseline (UAS7 >15).



## CONCLUSION

**Omalizumab** showed **long-term effectiveness** in **CIU** patients, maintaining **almost half of the patients** with **total response** and **almost a third** of patients with **adequate disease** control at 60 months.

## CONTACT DATA

**E-mail:** mangilsie@yahoo.com